Vaccines for gonorrhea: can we rise to the challenge? - sprookjes - yvandenbroek - TriplyDB

Vaccines for gonorrhea: can we rise to the challenge?

Vaccines for gonorrhea: can we rise to the challenge?

http://www.wikidata.org/entity/Q21131153

about

Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease Global analysis of neutrophil responses to Neisseria gonorrhoeae reveals a self-propagating inflammatory program Neisseria gonorrhoeae Evades Calprotectin-Mediated Nutritional Immunity and Survives Neutrophil Extracellular Traps by Production of TdfH.Phase-Variable Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine Antibody Directed against Neisseria gonorrhoeae Lipooligosaccharide.Assembly of NADPH oxidase in human neutrophils is modulated by the opacity-associated protein expression State of Neisseria gonorrhoeae Neisseria gonorrhoeae phagosomes delay fusion with primary granules to enhance bacterial survival inside human neutrophils.Quantitative proteomics of the Neisseria gonorrhoeae cell envelope and membrane vesicles for the discovery of potential therapeutic targets.Transition metals at the host-pathogen interface: how Neisseria exploit human metalloproteins for acquiring iron and zinc.Vaccines against gonorrhea: current status and future challenges.Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections.Antibodies with higher bactericidal activity induced by a Neisseria gonorrhoeae Rmp deletion mutant strain Sexually transmitted infections in Canada: A sticky situation.Molecular pathogenesis of Neisseria gonorrhoeae Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms.Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal A doctor's dilemma: choices amidst change The transferrin-iron import system from pathogenic Neisseria species.The reproductive cycle is a pathogenic determinant during gonococcal pelvic inflammatory disease in mice.Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12.Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.Control of Neisseria gonorrhoeae in the era of evolving antimicrobial resistance.Antibody-based concepts for multipurpose prevention technologies.Is gonorrhea becoming untreatable?Current and future treatment options for gonorrhoea.Vaccine research for gonococcal infections: where are we?Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae.Deciphering function of new gonococcal vaccine antigens using phenotypic microarrays.Multipurpose prevention technologies for reproductive and sexual health.Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae.Intravaginal Administration of Interleukin 12 during Genital Gonococcal Infection in Mice Induces Immunity to Heterologous Strains of Neisseria gonorrhoeae.Novel Whole-Cell Inactivated Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization

P2860

Q24633203-C4D3C790-4C71-434C-8CBF-7BE946916F5F Q27333895-02BA4EA4-07F0-46F7-8F09-5079FDB8A916 Q28083737-FE5634E8-6453-4024-9E65-C4EE19260D2C Q28542800-DFC5B9D3-3F10-4559-9EE7-068A0B221C86 Q30276223-275D5903-C0D3-485A-BA95-9BFC5DC2A1FB Q30352495-1C9B4331-8BB3-4A8D-9D50-FDDA814F4085 Q30411015-A6F93FE2-951D-46C3-AB13-9C1906BA0482 Q30411495-C33303A5-1DED-4815-A06B-18275EC2D7D6 Q33583183-CBFC74C4-449B-455C-84FC-36C8203F5319 Q33914938-057AE9E8-3A22-408D-AB66-A44EFAE0C81F Q34369729-FFA88D02-2B8B-472B-9502-20A8F8773EAE Q35086017-16E90B9B-1FFD-48BF-89E2-18EF465AF967 Q35110772-0EFC3457-4A42-4040-B7DD-74BA71848C28 Q35433936-61B1AF2C-74FC-4AD2-9BD3-A41FAF7D1222 Q35549839-D443B82E-F8B3-41A0-B70B-6E9FD0AF67A8 Q35894782-326F5982-E672-473D-92C8-2F046EF22333 Q36092095-0FEADE99-98B7-468E-B0FE-62536D0E7223 Q36106025-73B42F2D-06A0-4C88-86E1-C1B73B9FBF2A Q36309845-BC7BD78D-1940-4D42-9F49-CC110A2C27EC Q37026470-FC20D2DA-236A-4BB9-A7B9-4E950942DB45 Q37163672-92FA7E49-283D-4707-BC7B-489032554492 Q37266237-117593BB-7650-4E74-B19C-91281C3F187B Q37272314-2B2BBB75-A989-4555-9BC9-33B28E26D537 Q37347397-3A445C08-E0EB-4AD3-8EA2-79AE17FC8DF2 Q37349192-EA3C839A-64D6-4AC7-9632-5B683DD4AC7E Q37601003-2E5AA686-1112-442E-85CC-50A04BADCFB4 Q37844851-8B8BC783-6E8B-4309-9192-63DB10EF942F Q38150832-6C0B7A4B-2610-46B2-98EB-0F9B0C1B932F Q38163516-3789B826-AB28-4FA6-AFD7-52E5A4EFE7A0 Q40104608-CADCCE80-A1D6-48EF-9FAE-CC0395584ABD Q40166275-68145082-0827-4464-A184-99C6B02FCF55 Q41565172-D9AC7946-E451-4CF7-ABDE-B31C91D1979E Q45069667-0431645D-A0C6-41D2-88C6-0FDD217CE4A2 Q49880282-3D7745D4-4AC5-49BE-8257-DE4BDDF30E61 Q58764305-049A558A-FC5F-413C-A7C6-12AD94AD8521

P2860

Vaccines for gonorrhea: can we rise to the challenge?

http://www.wikidata.org/entity/Q21131153

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Vaccines for gonorrhea: can we rise to the challenge?

@ast

Vaccines for gonorrhea: can we rise to the challenge?

@en

Vaccines for gonorrhea: can we rise to the challenge?

@en-gb

Vaccines for gonorrhea: can we rise to the challenge?

@nl

type

label

Vaccines for gonorrhea: can we rise to the challenge?

@ast

Vaccines for gonorrhea: can we rise to the challenge?

@en

Vaccines for gonorrhea: can we rise to the challenge?

@en-gb

Vaccines for gonorrhea: can we rise to the challenge?

@nl

altLabel

Vaccines for Gonorrhea: Can We Rise to the Challenge?

@en

prefLabel

Vaccines for gonorrhea: can we rise to the challenge?

@ast

Vaccines for gonorrhea: can we rise to the challenge?

@en

Vaccines for gonorrhea: can we rise to the challenge?

@en-gb

Vaccines for gonorrhea: can we rise to the challenge?

@nl

P1433

Q21131153-844B64FD-9A13-44F9-B466-544B6444DCB1

P1476

Q21131153-721928DF-3379-469E-B005-EF59EDEBE865

P2093

Q21131153-374C1170-0F31-4BE6-99D6-BA976F00CC2B

Q21131153-767F86F0-DC74-4F42-AA60-557F9FAF51E6

Q21131153-91C89622-828A-4395-AFEC-A54BFB8B915A

Q21131153-A71AE3BD-06C8-4880-8784-95BB2C6DBF99

Q21131153-B9D48C4C-6679-4CAE-9F5E-5CD4EDA73F17

Q21131153-D9C76986-BDE9-4A11-84F7-8C42325ED8EA

P2860

Q21131153-018B134D-117E-40BC-86AB-7573C313CB55

Q21131153-01BBD452-8DD2-42FB-BCBE-44BA0EC58FD7

Q21131153-038C2290-4BC9-4738-A444-552E72F93844

Q21131153-0A96D173-FACE-48E7-BF63-43BF78A3BB7B

Q21131153-0B3F62CA-4EA9-4BD1-86AA-F3067EF9551A

Q21131153-0B56C461-0A39-49BA-8AE7-E0FE85905166

Q21131153-0D83742C-9DC2-4F1B-B650-AF8B770DD3F6

Q21131153-0F5A9B36-B79F-4836-B357-B4E953162F66

Q21131153-1080CE1A-965D-4D22-B676-33E27A760A36

Q21131153-12369B8C-9E3A-4FC0-A146-D2F809252185

P304

Q21131153-284C2C94-2C21-4933-9A4B-0B7EBA6A79D8

P31

Q21131153-2674955B-EC4D-4003-8E69-0161F154625E

P356

Q21131153-3CA471EA-5BBC-46D1-82EB-14C9C5A7AEE8

P407

Q21131153-6214B9CA-2F22-4629-8668-1F822625280B

P478

Q21131153-2B92C5B0-39C3-4526-9824-675FE1043480

P577

Q21131153-10588FCB-C710-4D13-8A78-C93884CD101F

P5875

Q21131153-F198CADA-AE85-47F0-B5E3-902E527906E7

P698

Q21131153-19EB6F74-919F-4D75-BDEF-C2D08E65D8D4

P921

Q21131153-F2CDAA3B-EF7D-436A-9C63-29CBD5D7C01B

P932

Q21131153-EBA95E2D-7019-4741-8CDE-70930C86B837

P356

FMICB.2011.00124

P1433

Frontiers in Microbiology

P1476

Vaccines for gonorrhea: can we rise to the challenge?

@en

P2093

Ann E Jerse

http://www.w3.org/2001/XMLSchema#string

Ching-Ju Chen

http://www.w3.org/2001/XMLSchema#string

Christopher E Thomas

http://www.w3.org/2001/XMLSchema#string

James E Anderson

http://www.w3.org/2001/XMLSchema#string

P Frederick Sparling

http://www.w3.org/2001/XMLSchema#string

Weiyan Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques

Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization

NadA, a novel vaccine candidate of Neisseria meningitidis

Structural and immunochemical characterization of a Neisseria gonorrhoeae epitope defined by a monoclonal antibody 2C7; the antibody recognizes a conserved epitope on specific lipo-oligosaccharides in spite of the presence of human carbohydrate epit

The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement

T-cell quality in memory and protection: implications for vaccine design

Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity

Bacterial porin disrupts mitochondrial membrane potential and sensitizes host cells to apoptosis.

The role of porins in neisserial pathogenesis and immunity.

Resistance of Neisseria gonorrhoeae to non-oxidative killing by adherent human polymorphonuclear leucocytes.

P304

124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FMICB.2011.00124

http://www.w3.org/2001/XMLSchema#string

P407

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51232849

http://www.w3.org/2001/XMLSchema#string

P698

21687431

http://www.w3.org/2001/XMLSchema#string

P921

P932

3109613

http://www.w3.org/2001/XMLSchema#string